Barclays
KPTI icon

Barclays’s Karyopharm Therapeutics KPTI Stock Holding History

Barclays’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41.4K Buy
7,424
+3,315
+81% +$25.3K ﹤0.01% 4385
2025
Q4 		$30.2K Hold
4,109
– – ﹤0.01% 4819
2025
Q3 		$26.9K Sell
4,109
-1,224
-23% -$6.58K ﹤0.01% 4896
2025
Q2 		$23K Hold
5,333
– – ﹤0.01% 4833
2025
Q1 		$19.9K Sell
5,333
-1,041
-16% -$8.89K ﹤0.01% 4789
2024
Q4 		$64.7K Sell
6,374
-10
-0.2% -$121 ﹤0.01% 4698
2024
Q3 		$79.5K Sell
6,384
-51,834
-89% -$644K ﹤0.01% 4629
2024
Q2 		$758K Sell
58,218
-1,303
-2% -$21.6K ﹤0.01% 2769
2024
Q1 		$1.35M Sell
59,521
-5,150
-8% -$90.3K ﹤0.01% 2887
2023
Q4 		$839K Sell
64,671
-12,149
-16% -$164K ﹤0.01% 3572
2023
Q3 		$1.54M Buy
76,820
+3,063
+4% +$68.7K ﹤0.01% 2044
2023
Q2 		$1.98M Sell
73,757
-116,069
-61% -$5M ﹤0.01% 1893
2023
Q1 		$11.1M Buy
189,826
+120,045
+172% +$5.93M 0.01% 1117
2022
Q4 		$3.56M Buy
69,781
+39,417
+130% +$2.73M ﹤0.01% 1870
2022
Q3 		$2.49M Buy
30,364
+24,902
+456% +$1.86M ﹤0.01% 1600
2022
Q2 		$369K Sell
5,462
-386
-7% -$35.4K ﹤0.01% 3069
2022
Q1 		$646K Sell
5,848
-6,269
-52% -$781K ﹤0.01% 2715
2021
Q4 		$1.17M Buy
12,117
+3,291
+37% +$328K ﹤0.01% 2728
2021
Q3 		$770K Sell
8,826
-4,426
-33% -$459K ﹤0.01% 2937
2021
Q2 		$2.05M Sell
13,252
-5,040
-28% -$731K ﹤0.01% 2175
2021
Q1 		$2.89M Buy
18,292
+2,928
+19% +$617K ﹤0.01% 1972
2020
Q4 		$3.57M Buy
15,364
+11,798
+331% +$2.73M ﹤0.01% 1773
2020
Q3 		$781K Sell
3,566
-1,235
-26% -$302K ﹤0.01% 2896
2020
Q2 		$1.36M Buy
4,801
+805
+20% +$238K ﹤0.01% 2469
2020
Q1 		$1.15M Sell
3,996
-1,827
-31% -$504K ﹤0.01% 2813
2019
Q4 		$1.67M Buy
5,823
+3,503
+151% +$760K ﹤0.01% 3185
2019
Q3 		$335K Sell
2,320
-690
-23% -$93.6K ﹤0.01% 4574
2019
Q2 		$270K Buy
3,010
+1,544
+105% +$124K ﹤0.01% 4835
2019
Q1 		$128K Buy
1,466
+808
+123% +$89.6K ﹤0.01% 5169
2018
Q4 		$92K Sell
658
-3,501
-84% -$591K ﹤0.01% 5093
2018
Q3 		$1.06M Buy
4,159
+2,356
+131% +$651K ﹤0.01% 3560
2018
Q2 		$459K Sell
1,803
-1,063
-37% -$263K ﹤0.01% 4031
2018
Q1 		$577K Buy
2,866
+964
+51% +$192K ﹤0.01% 3832
2017
Q4 		$273K Buy
1,902
+1,425
+299% +$229K ﹤0.01% 4421
2017
Q3 		$79K Sell
477
-1,963
-80% -$281K ﹤0.01% 5090
2017
Q2 		$331K Buy
2,440
+1,396
+134% +$207K ﹤0.01% 3909
2017
Q1 		$200K Buy
1,044
+626
+150% +$100K ﹤0.01% 4323
2016
Q4 		$59K Buy
418
+123
+42% +$16.6K ﹤0.01% 5059
2016
Q3 		$43K Buy
295
+260
+743% +$31.2K ﹤0.01% 5055
2016
Q2 		$4K Buy
35
+20
+133% +$2.6K ﹤0.01% 5792
2016
Q1 		$1K Sell
15
-20
-57% -$2.21K ﹤0.01% 5972
2015
Q4 		$7K Sell
35
-738
-95% -$160K ﹤0.01% 5487
2015
Q3 		$115K Buy
773
+739
+2,174% +$198K ﹤0.01% 4527
2015
Q2 		$14K Sell
34
-117
-77% -$50.6K ﹤0.01% 5889
2015
Q1 		$68K Buy
151
+78
+107% +$33.6K ﹤0.01% 5088
2014
Q4 		$41K Buy
73
+42
+135% +$23.9K ﹤0.01% 5863
2014
Q3 		$16K Buy
31
+15
+94% +$8.46K ﹤0.01% 6627
2014
Q2 		$11K Sell
16
-4
-20% -$1.86K ﹤0.01% 6784
2014
Q1 		$9K Buy
20
+12
+150% +$6.08K ﹤0.01% 6964
2013
Q4 		$2K Buy
+8
New +$2.21K ﹤0.01% 7360

Other funds holding KPTI

CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Barclays's KPTI Position: Q1 2026 in Review

Barclays increased its Karyopharm Therapeutics (KPTI) stake by 81% in Q1 2026, buying an estimated $25.3K and bringing the position to 7,424 shares worth $41.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4385.

Barclays first reported a position in KPTI in Q4 2013 and has held it in 50 quarters since. The position peaked at $11.1M in Q1 2023. 77 funds tracked by Wall St. Rank hold KPTI as of Q1 2026.

  • Barclays held 7,424 shares of Karyopharm Therapeutics worth $41.4K as of Q1 2026.
  • Barclays bought 3,315 Karyopharm Therapeutics shares in Q1 2026, an estimated $25.3K.
  • Karyopharm Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4385 holding.
  • Barclays first reported a position in Karyopharm Therapeutics in Q4 2013 and has held it in 50 quarters since.
  • Barclays's Karyopharm Therapeutics position peaked at $11.1M in Q1 2023.
  • 77 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.